• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Fischer suffers another poor quarter

Article

X-ray vendor Fischer Imaging continues to be plagued by a 50% drop in sales to OEMs. Hurt primarily by an ongoing decline in shipments of the Tilt-C tilting C-arm to GE Medical Systems, the Denver-based company reported a 31% drop in revenues in its

X-ray vendor Fischer Imaging continues to be plagued by a 50% drop in sales to OEMs. Hurt primarily by an ongoing decline in shipments of the Tilt-C tilting C-arm to GE Medical Systems, the Denver-based company reported a 31% drop in revenues in its second quarter (end-June).

Fischer posted revenues of $15.2 million, compared with $21.9 million in 1996. The company had a net loss of $1.4 million, compared with earnings of $946,000 in the same period in 1996.

While revenues were up 23% compared with the vendor's first-quarter results (SCAN 4/30/97), Fischer still remains sharply off last year's six-month pace. For the first six months of 1997, the company had revenues of $27.5 million, compared with $42 million in the same period in 1996. Fischer reported a net loss of $5.3 million in the first half, compared with net income of $2 million in 1996.

The news from Fischer wasn't all bad, however. Mammography system sales were up 42% in the second quarter, and the company has reduced its inventory in the first half of the year by $5.2 million. Fischer has $5.1 million in cash and remains essentially debt-free, according to Morgan Nields, chairman and CEO.

The company's primary R&D objective remains the completion of a clinical trial for its SenoScan full-field digital mammography system, which is now operating at five centers in the U.S. and Canada. Some of these sites are gathering data to support the company's 510(k) submission to the Food and Drug Administration, according to the company.

Related Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.